Detalhe da pesquisa
1.
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38572562
2.
Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Haematologica
; 2024 May 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38813716
3.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Am J Hematol
; 99(4): 606-614, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38342997
4.
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Haematologica
; 108(7): 1900-1908, 2023 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36779595
5.
Capsule Commentary on Zheng et al., The Role of Spirituality in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Mixed Studies Review.
J Gen Intern Med
; 35(7): 2253, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32462571
6.
The Impact of Beta-Blocker Use at the Time of Hematopoietic Cell Transplantation on the Development of Acute and Chronic Graft-Versus-Host Disease.
Hematol Oncol Stem Cell Ther
; 16(3): 209-216, 2023 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34780786
7.
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Leukemia
; 37(4): 799-806, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36807649
8.
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.
Transplant Cell Ther
; 27(11): 911.e1-911.e7, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34450333
9.
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Blood Cancer J
; 14(1): 32, 2024 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38378617
10.
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.
Leuk Res
; 132: 107348, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37423073